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Abstract: The presence of circulating tumor cells (CTCs) in patients with metastatic carcinoma is generally 
associated with poor clinical outcome. There have been many investigations showing a possible use of CTCs as 
minimally invasive predictive and prognostic biomarker in cancer medicine. In this report a size-based method 
(MetaCell®) for quick and easy enrichment and cultivation of CTCs is presented to enable possible CTCs use 
in esophageal cancer (EC) management. In total, 43 patients with diagnosed EC, 20 with adenocarcinoma 
(Adeno Ca) and 23 with squamous cell carcinoma (SCC), were enrolled into the adaptive prospective-like study. 
All the patients were candidates for surgery. The CTCs were detected in 27 patients (62.8%), with a higher rate 
in adenocarcinoma (75%) than SCC (52%). Finally, there were 26 patients with resectable tumors exhibiting 
CTCs-positivity in 69.2% and 17 patients with non-resectable tumors with 41.7% CTCs-positivity. Interestingly, 
in the patients undergoing neoadjuvant therapy, the CTCs were detected at time of surgery in 55.5% (10/18). The 
overall size-based filtration approach enabled to isolate viable CTCs and evaluate to their cytomorphological 
features by means of vital fluorescent staining. The CTCs were cultured in vitro for further downstream appli-
cations including immunohistochemical analysis. This is the first report of the successful culturing of esophageal 
cancer CTCs. The detection of CTCs presence could help in the future to guide timing of surgical treatment in 
EC patients.  (Folia Histochemica et Cytobiologica 2014, Vol. 52, No. 3, 171–177)
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Introduction
Esophageal cancer (EC) is currently the most rapidly 
increasing cancer in the U.S. and Western Europe [1]. 
EC is the eighth most common cancer and the sixth 
most common cause of cancer death worldwide, 
affecting more male than female [2]. The survival 
and prognosis of EC patients depend on the stage 
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of the tumor at the time of detection. Early tumor 
diagnosis, improved surgical treatment and multimo-
dal therapeutic concepts have helped to reduce the 
mortality of EC patients. Nevertheless, the survival 
rates of these patients are still highly unsatisfactory. 
The prognosis depends on local tumor recurrence 
and/or the occurrence of distant metastases. Esoph-
ageal cancer is notorious for its aggressive biological 
behavior, local infiltration, involvement of adjacent 
lymph nodes, and metastasis through hematogenous 
spread. It has been reported that the frequency of 
hematogenous recurrence was high despite radical 
surgery with lymph node dissection [3]. In this regard, 
the detection of cancer cells in the blood could be 
important in identifying patients with high relapse 
risk. The presence of CTCs in patients with meta-
static carcinoma is generally associated with poor 
clinical outcome [4]. This has been shown for both 
malignancies in the gastrointestinal tract [5, 6] and 
other cancers [7, 8]. 
Many investigations showed a positive correlation 
between detection of circulating tumor cells (CTCs), 
tumor staging and patient prognosis. Therefore, in 
general, CTCs are thought to provide additional 
prognostic information for the TNM classification. 
Similarly, it is hoped that CTCs detection could help 
to guide the surgery timing in EC patients, especially 
in the group of EC patients undergoing neoadjuvant 
chemotherapy. We report a new method for quick 
and easy enrichment and cultivation of CTCs isolated 
from the EC patients’ blood. 
Material and methods
Patients. To date, 43 patients with diagnosed EC, 20 ade-
nocarcinomas (AdenoCa) and 23 squamous cell carcinomas 
(SCC), localized in esophagus or stomach maximally 5 cm 
from gastro-esophageal junction, were enrolled into the 
study in accordance with the Declaration of Helsinki. All 
patients were candidates for surgery treatment. Based on the 
informed consent, the clinical data were collected from all 
participating patients. The patient characteristics are shown 
in Table 1. Peripheral blood was collected prior to surgery. 
For each patient, approximately 8 mL of venous blood was 
drawn from the antecubital vein into S-Monovette tubes 
(Sarstedt AG & Co., Numbrecht, Germany) containing 
1.6 mg EDTA/mL blood as an anticoagulant. The samples 
were processed at room temperature using an isolation 
procedure completed within 24 hours after the blood draw. 
The biological material has been collected in a prospecti-
ve time matter; however this was not a clinical study, but 
experimental one which aimed to test the feasibility of a new 
CTC isolation method. 
CTCs enrichment and culture. Recently, a new size-based 
separation method for viable CTCs — enrichment from 
unclotted peripheral blood has been introduced (MetaCell®, 
MetaCell s.r.o., Ostrava, Czech Republic). The size-based 
enrichment process is based on the filtration of peripheral 
blood (PB) through porous polycarbonate membrane 
(pores with diameter of 8 μm). The minimum and maximum 
volume of the filtered PB may be adjusted up to 50 mL 
of fluid. Routinely, 8 mL PB from EC patients was trans-
ferred into the filtration tube. The PB flow through filter 
is supported by capillary action of the absorbent touching 
the membrane filter. The whole isolation procedure was 
performed at room temperature. The enriched CTCs were 
observed on the membrane immediately after filtration by 
inverted light microscopy and subsequently (after 2 hours) 
by fluorescent microscopy using unspecific vital nuclear stain 
(NucBlue, Life Technologies). For some of the tested 
samples unspecific cytoplasmic vital stain (CellTracker, 
Life Technologies) was used to identify viable CTCs. The 
fluorescent analysis enables to distinguish cytomorphology 
of the recently enriched CTC fraction with a very high per-
centage of sensitivity. The presence of the isolated CTCs 
controlled immediately after the isolation process helped 
to avoid false negative results. 
Afterwards, the membrane filter kept in a plastic ring was 
transferred into the 6-well culture plate, 4 mL RPMI media 
was added to the filter top and CTCs were cultured under 
standard conditions on the membrane in vitro under condi-
tions of standard cancer cell cultures (5% CO2, 37°C) and 
observed by inverted microscope. The CTCs are grown in 
the 10% fetal bovine serum-enriched RPMI medium for the 
period of maximum 14 days. The cultured cells were stained 
by the May-Grünwald method and immunohistochemistry 
using the tumor-specific antibodies to prove the cell origin 
(antiCK18-FITC, Sigma-Aldrich, Steinheim, Germany) 
and to visualize cell nuclei (DAPI staining, Sigma-Aldrich).
Next, the enriched CTCs fraction was transferred from 
the membrane and cells were cultured directly on the plastic 
surface or microscopic slides. Microscopic slide culture is 
preferred if the immunohistochemistry/immunofluore-
scence analysis is planned. If intermediate CTCs-analysis 
is planned, the CTCs fraction is transferred in phospha-
te-buffered saline (1,5 mL PBS) to the cytospin slide. The 
slide was then dried for 24 hours and analyzed by means of 
immunohistochemistry.
Cytomorphological analysis. The fixed and stained cells on 
the membrane were examined using light and fluorescence 
microscopy. The analytical process can be divided into two 
steps: (1) observing at smaller magnification (up to 20 ×) 
to identify cells or cell nuclei, (2) observing at higher mag-
nification (up to 60 ×) for more detailed evaluation of 
cytomorphology. 
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Cells captured on the separating membrane (single cells 
or cells in clusters) were identified, the photographs were 
digitized, and evaluated by a trained researcher and/or 
experienced pathologist. Cells presenting characteristics 
listed below were defined as CTCs due to the presence of 
the following criteria: (a) nuclear size equal or larger than 
10 μm; (b) presence of a visible cytoplasm; (c) prominent 
nucleoli (d) high nuclear-cytoplasmic ratio, which was not 
necessarily true in case of in vitro cultured cells (e) irregular 
nuclear contour. 
Results 
We report here successful CTCs detection in the blo-
od of EC patients (Figures 1–3). Table 1 shows that 
the CTCs were detected in 27/43 patients (62.8%). 
Detection of CTCs was higher in patients with ade-
nocarcinoma (75%) than squamous cell tumor (52%), 
and this might be caused by the disproportion in the 
numbers of patients in different stadium of the disease 
in the adenocarcinoma and squamous cell carcinoma 
subgroups. 
The overall size-based filtration approach ena-
bled to isolate viable CTCs (Figure 2). The general 
characteristics of the captured CTCs is a relatively 
big nucleus (more than 10 µm, Figure 1), which 
shows prominent nucleoli (4 and more) reflecting 
the transcriptional activity of the cells. This feature 
reflects the potential of CTCs to survive under the in 
vitro conditions. We are able to grow the EC CTCs 
maximally for 14 days. We could not obtain confluent 
cultures of these cells; however, we observed two types 
of subcultures during the cultivation process. The first 
one was composed of cells which grew on the membra-
ne (Figure 1) while the second one consisted of cells 
which were growing through the pores in the membrane 
and formed colonies on the bottom of a culture well. 
Culturing of the esophageal cancer CTCs in vitro 
enabled to have more biological material to further cha-
racteristics such as immunohistochemical analysis: we 
Table 1. Characteristics of the esophageal cancer of the studied patients
Patients 
(n)
with 
CTCs
(%) AdenoCa 
(n)
with 
CTCs
(%) SCC (n) with 
CTCs
%
Total 43 27 62.8 20 15 75 23 12 52.2
T stage
T1 1 0 0 0 0 0 1 0 0
T2 3 3 100 1 1 100 2 2 100
T3 23 13 56.5 16 11 68.8 7 2 28.6
T4 16 10 62.5 3 2 66.7 13 8 61.5
N stage
N0 10 7 70 4 3 75 6 4 66.7
N1 11 5 45.5 7 5 71.4 4 0 0
N2 9 6 66.7 5 4 80 4 2 0.5
N3 13 9 69.2 4 3 75 9 6 66.7
M stage
M0 35 24 68.6 18 14 77.8 17 10 58.8
M1 8 3 37.5 2 1 50 6 2 33.3
Disease stadium
I 4 3 75 1 1 100 3 2 66.7
II 5 3 60 3 2 66.7 2 1 50
III 26 18 69.2 14 11 78.6 12 7 58.3
IV 8 3 37.5 2 1 50 6 2 33.3
Others
Resectable 26 18 69.2 14 11 78.6 12 7 58.3
Non-resectable 17 7 41.9 6 2 33.3 11 5 45.4
Neoadjuvant therapy 18 10 55.6 15 10 83.3 3 0 0
AdenoCa — adenocarcinoma; CTCs — circulating tumor cells; SCC — squamous cell carcinoma
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used this method to detect in the CTCs cytokeratin 18 to 
prove their epithelial (gastroepithelial) origin (Figure 3). 
We do not have recently the survival analysis of 
the tested patients group, but thanks to the obtained 
data, we were able to characterize the CTCs dissemi-
nation in the pre-defined patient subgroups (Table 1). 
Interestingly patients with resectable EC were in 
69.2% cases CTCs-positive, while in the group with 
non-resectable EC only 42.9% patients showed 
CTCs positivity. This might have been caused by the 
fact, that some of the non-resectable patients were 
undergoing the neoadjuvant chemotherapy resulting 
in the decrease of CTCs in the blood. Unfortunately, 
we do not have all data concerning neoadjuvancy yet. 
So far the neoadjuvant therapy was administered to 
18 patients. From these 18 patients, there CTCs were 
detected in 10 (55.5%). All these patients have been 
undergoing only chemotherapy treatment. This in ge-
neral confirms a very advanced stage of the disease, as 
could be expected if neoadjuvant therapy is planned. 
Nevertheless the CTCs-positivity reflects the 
disease stadium as well as lymph node involvement. 
Moreover, there are more patients affected by the 
spread of the CTCs in stage III than in stage IV of 
the disease, which may be caused by the small number 
of the patients in this subgroup indicated to primary 
tumor resection. 
Discussion
In the presented study we report the CTCs detection 
in the blood of EC patients and their subsequent in 
vitro culture. The study was not designed to reflect the 
survival analysis, but to answer the question, if it could 
be possible to isolate viable EC-CTCs which could be 
cultured in vitro. The data on the CTCs presence could 
be than further used for patient stratification in case 
of neoadjuvant treatment and surgery. The in vitro 
cultures can be also a source of biological material 
for further downstream analysis. 
Figure 1. Circulating tumor cells (CTCs) captured on the porous membrane filter, stained by May-Grünwald method.  
A and B. CTCs after 1 day in culture. C and D. CTCs cultured for 3 days in vitro. Scale bar 10 µm
A B
C D
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The detection of CTCs in blood requires highly 
sensitive, specific, and reproducible methods. Various 
techniques are available to isolate CTCs from blood 
by exploiting their unique properties, including tissue 
specific nucleic sequences, cell surface markers and 
physical properties. Investigators have used different 
blood collection volumes, sample processing methods 
and criteria to define CTCs [9]. Antibody-based 
immuno-identification has been the mainstream for 
CTCs detection. This strategy, however, is limited by 
the availability and specificity of the antibodies. 
In the past detection of CTCs from peripheral blood 
(PB) of EC patients by quantitative PCR (qPCR) has 
been reported as a very promising using several genes. 
Liu et al. aimed at establishing a quantitative system 
for evaluating the role of CTCs in blood from patients 
who underwent surgical resection in the treatment 
of EC [10]. One hundred fifty-five PB samples from 
53 EC patients were collected before the surgery 
(B-1), immediately after surgery (B0), and on the 
Figure 2. CTCs captured on the membrane filter visualized by blue vital nuclear stain (NucBlueTM) and green vital cy-
toplasmic stain (CellTrackerTM). Scale bar 10 µm. Big nuclei with irregular contours were observed very often
A B
C D
Figure 3. CTCs captured on the membrane filter. The cell 
origin has been visualized by anti-CK18 antibody (FITC-la-
belled). The nucleus was visualized by DAPI-staining. Scale 
bar 10 µm
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3rd day postoperatively (B+3). A qPCR method based 
on carcinoembryonic antigen (CEA) mRNA gene 
expression was designed for the detection of CTCs. 
The authors showed a significant difference between 
B-1 and B0 (p = 0.0001) and between B-1 and B+3 
(p = 0.0209). Fifty percent of patients with r > 0.4 
(r = CTC ratio of B+3 over B0) showed tumor 
recurrence within 1 year after surgery, whereas the 
probability was only 14.3% for patients with r < 0.4 
(p = 0.043). This report indicates a prognostic utility 
of CTCs evaluation in EC. 
Furthermore, qPCR of tumor-specific mRNA 
is characterized by higher sensitivity in comparison 
to protein-based methods and usually ranges within 
a detection range of 1 to 10 tumor cells among 106–107 
blood mononuclear cells [11]. Nevertheless, the high 
sensitivity of qPCR is problematic when false-positive 
results are encountered, as it is the case with sample 
contamination (genomic DNA versus cDNA) and 
illegitimate transcription (low-level nonspecific tran-
scription of certain genes) [11]. 
In recent years, a great number of molecular 
markers have been identified in the pathogenesis 
of EC which could be used as potential predictive 
and prognostic markers. These markers are mainly 
associated with the six hallmarks of cancer: self-suf-
ficiency in growth signals; insensitivity to antigrowth 
signals; avoidance of apoptosis; limitless replicative 
potential; sustained angiogenesis; and tissue invasion 
and metastasis [12]. 
Tumor markers such as cytokeratin 19, cytokera-
tin 20, squamous cell carcinoma antigen (SCC-Ag), 
deltaNp63, and CEA have all been used with varying 
degrees of sensitivity and specificity [9, 13–18]. How-
ever, these studies have also revealed a major problem 
in that some of these tumor markers are expressed in 
normal blood cells and frequently in normal epithelial 
cells as well. This inevitably leads to false-positive 
results that greatly diminish the correlation between 
tumor markers and some of the well-known clinical 
and pathological prognostic factors. 
To enhance the prediction power of mRNA mar-
ker, a combination of markers should be tested. As 
the amount of CTCs material is limited, the in vitro 
culture of CTCs, such as demonstrated in our study, 
could help to overcome these problems. 
Other studies provide evidence that some tumor 
cells may undergo full or partial epithelial-to-mesen-
chymal transition (EMT) during the process of inva-
sion and intravasation. Likewise, cells may undergo 
mesenchymal-to-epithelial transition after EMT to 
re-express some markers that were previously lost [19, 
20]. Cells that have undergone EMT are associated 
with a stem cell phenotype and may resist apoptotic 
signals, making them more likely to survive in circu-
lation and create deposits of therapeutically resistant 
metastasis [21]. 
Additionally, during the enrichment process by 
capturing CTCs there is a significant loss of CTCs; this 
loss could be of great importance given the fact that 
tumor cells represent less than 0.1% of the enriched 
population [22]. In general there are conflicting re-
sults concerning the superiority of immunomagnetic 
enrichment over traditional methods: although consi-
dered to provide greater specificity, immunomagnetic 
enrichment has been shown to be hampered by poor 
sensitivity [23].
Nagrath et al. demonstrated that the average CTCs 
number per mL of whole blood was approximately 
only 79–155 in various cancers [24]. Similarly, in 
contrast to the FDA-cleared CellSearch epithelial 
markers-based method [25], an investigative ‘CellSe-
arch profile approach’ could detect an approximately 
30-folds higher number of the median CTCs counts 
by using the same paired blood samples in breast can-
cer [26]. These findings indicate that the actual CTCs 
numbers in patients’ blood could be at least 30–100 
times higher than that currently reported by the only 
FDA-cleared CellSearch system. 
Size-based isolation techniques of CTCs have 
the advantage to be independent of antibody 
availability. We used MetaCell® protocol with 
pre-defined pores filter which enables quick iso-
lation of CTCs from blood without affecting the 
cells by interaction with detecting antibody or lys-
ing solution. We proved that these CTCs are then 
suitable for subsequent culturing. The CTCs are 
separated independently on the heterogeneity or 
pleomorphism of CTCs. The CTCs enriched from 
blood on the separating membrane are labeled as 
‘virgin CTCs’ since these are the most similar to 
metastatic tumor present in circulation. These cells 
are suitable to be cultured and perform subsequent 
molecular testing with regard to monitoring of 
chemotherapy efficiency. 
Changes in the counts of CTCs appear to reflect 
more rapidly the impact of the anti-cancer treat-
ment, which can be otherwise reported in as little 
as a few weeks. Beyond an in vitro number count, 
an ex vivo functional study on patient-derived CTCs 
might support an immediate treatment decision 
regarding surgery eligibility. To reveal the real-ti-
me, individualized drug-target interaction, viable 
CTCs, immediately enriched from cancer patient’s 
blood, can be also used to target new anti-cancer 
drug candidates. 
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